These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 20564380

  • 1. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
    Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K.
    Hepatology; 2010 Jul; 52(1):197-203. PubMed ID: 20564380
    [Abstract] [Full Text] [Related]

  • 2. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E, Trottier J, Milkiewicz M, Raszeja-Wyszomirska J, Hirschfield GM, Barbier O, Milkiewicz P.
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [Abstract] [Full Text] [Related]

  • 3. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC, Wolfhagen FH, Van Berge-Henegouwen GP, Salemans JM, Tangerman A, van Buuren HR, van Hattum J, van Erpecum KJ.
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [Abstract] [Full Text] [Related]

  • 4. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F.
    Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
    Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK.
    Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
    Verma A, Jazrawi RP, Ahmed HA, Davis T, Bland JM, Benson M, Orchard RT, Theodossi A, Maxwell JD, Northfield TC.
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T, Befeler AS.
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Changes in bile acid composition and effect on cytolytic activity of fecal water by ursodeoxycholic acid administration: a placebo-controlled cross-over intervention trial in healthy volunteers.
    van Gorkom BA, van der Meer R, Boersma-van Ek W, Termont DS, de Vries EG, Kleibeuker JH.
    Scand J Gastroenterol; 2002 Aug; 37(8):965-71. PubMed ID: 12229974
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.